RU2334517C2 - Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство - Google Patents

Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство Download PDF

Info

Publication number
RU2334517C2
RU2334517C2 RU2005131839/15A RU2005131839A RU2334517C2 RU 2334517 C2 RU2334517 C2 RU 2334517C2 RU 2005131839/15 A RU2005131839/15 A RU 2005131839/15A RU 2005131839 A RU2005131839 A RU 2005131839A RU 2334517 C2 RU2334517 C2 RU 2334517C2
Authority
RU
Russia
Prior art keywords
antitumor
tegafur
amount
gimeracil
effect
Prior art date
Application number
RU2005131839/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2005131839A (ru
Inventor
Дзундзи УТИДА (JP)
Дзундзи Утида
Койо СУДО (JP)
Койо СУДО
Original Assignee
Тайхо Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайхо Фармасьютикал Ко., Лтд. filed Critical Тайхо Фармасьютикал Ко., Лтд.
Publication of RU2005131839A publication Critical patent/RU2005131839A/ru
Application granted granted Critical
Publication of RU2334517C2 publication Critical patent/RU2334517C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2005131839/15A 2003-03-14 2004-03-11 Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство RU2334517C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003070097 2003-03-14
JP2003-070097 2003-03-14

Publications (2)

Publication Number Publication Date
RU2005131839A RU2005131839A (ru) 2006-02-10
RU2334517C2 true RU2334517C2 (ru) 2008-09-27

Family

ID=32984641

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005131839/15A RU2334517C2 (ru) 2003-03-14 2004-03-11 Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство

Country Status (21)

Country Link
US (2) US9611227B2 (fr)
EP (1) EP1604991B1 (fr)
JP (1) JP4610481B2 (fr)
KR (1) KR100812693B1 (fr)
CN (2) CN101357134A (fr)
AT (1) ATE408408T1 (fr)
AU (1) AU2004220205B2 (fr)
BR (1) BRPI0408372A (fr)
CA (1) CA2518195C (fr)
CY (1) CY1108395T1 (fr)
DE (1) DE602004016636D1 (fr)
DK (1) DK1604991T3 (fr)
ES (1) ES2312978T3 (fr)
MX (1) MXPA05009781A (fr)
NZ (1) NZ542150A (fr)
PL (1) PL1604991T3 (fr)
PT (1) PT1604991E (fr)
RU (1) RU2334517C2 (fr)
SI (1) SI1604991T1 (fr)
TW (1) TW200503720A (fr)
WO (1) WO2004081012A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657783C2 (ru) * 2013-09-30 2018-06-15 Тайхо Фармасьютикал Ко., Лтд. Комбинированная терапия с использованием азабициклосоединения для ракового заболевания

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137640A1 (en) * 2005-04-01 2009-05-28 Taiho Pharmaceutical Co.Ltd Potentiator for radiation therapy comprising pyridine derivative as active ingredient
WO2006106983A1 (fr) * 2005-04-01 2006-10-12 Taiho Pharmaceutical Co., Ltd. Agent radiosensibilisant
WO2007043531A1 (fr) * 2005-10-07 2007-04-19 Celestar Lexico-Sciences, Inc. Marqueur génétique destiné à être utilisé dans le diagnostic de sensibilité à un agent antitumoral ou à une chimiothérapie concurrente et utilisation de celui-ci
WO2009139085A1 (fr) * 2008-05-12 2009-11-19 静岡県 Agent antitumoral, kit et procédé de traitement du cancer
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
JP5566376B2 (ja) * 2009-04-22 2014-08-06 大鵬薬品工業株式会社 腎細胞癌に対する化学療法の治療効果予測方法
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
AU2012259803B2 (en) * 2011-05-25 2016-03-17 Taiho Pharmaceutical Co., Ltd. Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
CN106581001B (zh) * 2016-11-03 2018-12-21 江苏恒瑞医药股份有限公司 一种替吉奥组合物的制备方法
KR102258514B1 (ko) 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194430C (nl) 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
DK0500953T3 (da) * 1990-09-07 1997-01-06 Taiho Pharmaceutical Co Ltd Potentiator af antineoplastisk virkning og antineoplastisk middel
CA2087540C (fr) 1991-05-27 1999-01-19 Tetsuhiko Shirasaka Composition, methode et trousse pour potentialiser l'action antitumorale et traiter le cancer
CH683262A5 (it) * 1992-01-22 1994-02-15 Applied Pharma Res Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico).
AU2001240001A1 (en) * 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
KR20030081496A (ko) 2001-03-06 2003-10-17 브리스톨-마이어스 스큅 컴퍼니 테가푸르, 우라실, 폴린산, 파클리탁셀 및 카르보플라틴투여를 통한 종양 치료 방법 및 이들의 투여 형태
WO2003004640A1 (fr) * 2001-07-05 2003-01-16 Taiho Pharmaceutical Co., Ltd. Reseaux d'adn permettant de mesurer la sensibilite a un agent anticancereux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kazumasa IKEDA et al. Koshuyo Zai «TS1» no Yakuri Sayo to Tainai Dotai. Antibiotics & Chemotherapy. 17(7), pages 1318 to 1331 (2001). *
MARTONI A. et al. Weekly Regimen of 5-FU vs 5-FU+Intermediate Dose Folinic Acid in the Treatment of Advanced Colorectal Cancer. ANTICANCER RESEARCH. 12: 607-612, (1992). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657783C2 (ru) * 2013-09-30 2018-06-15 Тайхо Фармасьютикал Ко., Лтд. Комбинированная терапия с использованием азабициклосоединения для ракового заболевания

Also Published As

Publication number Publication date
WO2004081012A1 (fr) 2004-09-23
PL1604991T3 (pl) 2009-02-27
SI1604991T1 (sl) 2009-02-28
TWI295173B (fr) 2008-04-01
BRPI0408372A (pt) 2006-03-21
CA2518195A1 (fr) 2004-09-23
ES2312978T3 (es) 2009-03-01
CA2518195C (fr) 2009-07-07
JP4610481B2 (ja) 2011-01-12
US9611227B2 (en) 2017-04-04
MXPA05009781A (es) 2005-10-26
ATE408408T1 (de) 2008-10-15
RU2005131839A (ru) 2006-02-10
AU2004220205A1 (en) 2004-09-23
EP1604991A1 (fr) 2005-12-14
JPWO2004081012A1 (ja) 2006-06-08
US20060116345A1 (en) 2006-06-01
KR100812693B1 (ko) 2008-03-13
EP1604991A4 (fr) 2006-05-03
TW200503720A (en) 2005-02-01
NZ542150A (en) 2009-09-25
CN101357134A (zh) 2009-02-04
US20170157131A1 (en) 2017-06-08
KR20050106119A (ko) 2005-11-08
CN1761665A (zh) 2006-04-19
EP1604991B1 (fr) 2008-09-17
DE602004016636D1 (de) 2008-10-30
US9814724B2 (en) 2017-11-14
AU2004220205B2 (en) 2010-06-17
DK1604991T3 (da) 2009-01-05
PT1604991E (pt) 2008-10-27
CY1108395T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
ES2333348T3 (es) Combinaciones que comprenden epotilonas e inhibidores de la proteina tirosina quinasa y usos farmaceuticos de las mismas.
US20120157472A1 (en) Method for treating colorectal cancer
EP1757283B1 (fr) Agent renforçant un effet antitumoral, agent antitumoral et procédé de thérapie pour le cancer
US20190231793A1 (en) Use of harringtonines in the treatment of breast cancer, in particular triple-negative breast cancer
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
EP1667719B1 (fr) Traitement de tumeurs de stroma du tube digestif avec l'imatinibe et la midostaurine
JP2003300888A (ja) 抗腫瘍効果増強剤